Avacta is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer technology is a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. Following the Placing early in the current fiscal year to fund an in-house therapeutic Affimer programme, this has added a significant new element to the R&D spend which means that it is necessary for the company to change the method by which certain R&D investment is accounted for.
